CANDEL THERAPEUTICS INC

NASDAQ: CADL (Candel Therapeutics, Inc.)

Kemas kini terakhir: 10 Apr, 10:37AM

4.80

-0.30 (-5.89%)

  • 1H -5.89%
  • 5H -0.31%
  • 1B 0.74%
  • 6B -0.93%
  • Tahun Ke Tarikh -46.66%
  • 1T -55.14%
  • 5T -31.50%
Penutupan Terdahulu 5.10
Buka 4.70
Jumlah Dagangan 231,148
Purata Dagangan (3B) 1,227,268
Modal Pasaran 226,494,224
Harga / Jualan (P/S) 436.42
Harga / Buku (P/B) 3.37
Julat 52 Minggu
3.79 (-21%) — 14.60 (204%)
EPS Cair (TTM) -1.74
Jumlah Hutang/Ekuiti (D/E MRQ) 14.61%
Nisbah Semasa (MRQ) 4.64
Aliran Tunai Operasi (OCF TTM) -27.20 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -8.33 M
Pulangan Atas Aset (ROA TTM) -32.31%
Pulangan Atas Ekuiti (ROE TTM) -98.14%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Candel Therapeutics, Inc. Menurun Menaik

AISkor Stockmoo

1.4
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 1.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CADL 226 M - - 3.37
EXEL 12 B - 19.34 4.73
TGTX 5 B - 137.44 26.86
KRYS 5 B - 62.59 5.11
ADMA 5 B - 23.44 15.26
SRPT 4 B - - 3.13

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 20.83%
% Dimiliki oleh Institusi 43.27%

Pemilikan

Nama Tarikh Syer Dipegang
Northpond Ventures, Llc 30 Sep 2024 1,935,215
Sands Capital Ventures, Llc 31 Dec 2024 405,837
23.5023.5019.0019.0014.5014.5010.0010.005.505.50Harga Sasaran MedianQ3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
3.79 (-21%) — 14.60 (204%)
Julat Harga Sasaran
19.00 (296%) — 25.00 (421%)
Tinggi 25.00 (Canaccord Genuity, 421.38%) Beli
Median 22.00 (358.81%)
Rendah 19.00 (HC Wainwright & Co., 296.25%) Beli
Purata 22.00 (358.81%)
Jumlah 2 Beli
Harga Purata @ Panggilan 6.72
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 11 Apr 2025 19.00 (296.25%) Beli 4.97
14 Mar 2025 19.00 (296.25%) Beli 8.75
Canaccord Genuity 26 Feb 2025 25.00 (421.38%) Beli 8.47

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
22 May 2025 Pengumuman Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
13 May 2025 Pengumuman Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
06 May 2025 Pengumuman Candel Therapeutics to Present at Upcoming Investor Conferences
23 Apr 2025 Pengumuman Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
09 Apr 2025 Pengumuman Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation
01 Apr 2025 Pengumuman Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
26 Mar 2025 Pengumuman Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
20 Mar 2025 Pengumuman Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
18 Mar 2025 Pengumuman Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
13 Mar 2025 Pengumuman Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
25 Feb 2025 Pengumuman Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Papar semua
5.725.725.215.214.714.714.214.213.713.71May 7May 7May 8May 8May 9May 9May 12May 12May 13May 13May 14May 14May 15May 15May 16May 16

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
-0.000-0.000-0.200-0.200-0.400-0.400-0.600-0.600-0.800-0.800MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda